Costs and cost analysis · Neutropenia · Leukopenia · Health resources · Combined antineoplastic treatment protocols · Adverse effects Summary Background: Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited. Patients and Methods: A prospective, multicentre, longitudinal, observational study was carried out to evaluate the occurrence of FN/FL and its impact on health resource utilization and costs in non-small cell lung cancer (NSCLC), lymphoproliferative disorder (LPD), and primary breast cancer (PBC) patients. Costs are presented from a hospital perspective. Results: A total of 325 consecutive patients (47% LPD, 37% NSCLC, 16% PBC; 46% women; 38% age ≥ 65 years) with 68 FN/FL episodes were evaluated. FN/FL occurred in 22% of the LPD patients, 8% of the NSCLC patients, and 27% of the PBC patients. 55 FN/FL episodes were associated with at least 1 hospital stay (LPD n = 34, NSCLC n = 10, PBC n = 11). Mean (median) cost per FN/FL episode requiring hospital care amounted to € 3,950 (€ 2,355) and varied between € 4,808 (€ 3,056) for LPD, € 3,627 (€ 2,255) for NSCLC, and € 1,827 (€ 1,969) for PBC patients. 12 FN/FL episodes (LPD n = 9, NSCLC n = 3) accounted for 60% of the total expenses. Main cost drivers were hospitalization and drugs (60 and 19% of the total costs). Conclusions: FN/FL treatment has economic relevance for hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients. The impact of clinical characteristics on asymmetrically distributed costs needs further evaluation.
Introduction
Febrileneutropenia(FN)isconsideredapotentiallife-threatening emergency in patients receiving myelosuppressive chemotherapy(CTX)forcancer.Aspatientswithareduced whitebloodcellcount(WBC)areespeciallyvulnerabletoall kindsofinfections [1] andfeverisoftentheonlywarningsign, immediatemedicalattentionisnecessarytopreventinfection asearlyaspossible [2] .Therefore,FNusuallyleadstohospitalizationandtreatmentwithbroadspectrumantibiotics [3] . Theresultisoftenadoselimitationuptoadelayofthenext CTXcycle [4, 5] .
Asidefromtheclinicalconsequences,routinemanagement ofneutropeniaandFNhasaconsiderableeconomicimpact, particularlyintheinpatientsetting [6] .Currently,theexisting healtheconomicliteraturemainlyoriginatesfromtheUnited States.Meancostsforneutropenia-relatedcarethererecently were $12,397 per patient [7] . With $19,110, mean costs per episodeassociatedwiththemoresevereFNcanbemarkedly higher [8] . Moreover, cancer type and level of care seem to haveasubstantialimpactonFNmanagementcosts.Inapilot study with community oncology cancer patients, total direct inpatientcostswereonaverage$17,869forlymphomacom-paredto$10,354forbreastcancerpatients [9] .Directcostsfor outpatientswereremarkablylower(lymphoma:$5,704;breast cancer:$1,094).
American data tend to report substantially higher costs thanthoseforEurope.ASpainretrospectivestudyestimates €3,841meandirectcostperepisodeattributabletoFN [10] . Althoughpressureonhealthcarebudgetsisconstantlyrising, especially for Germany microeconomic data on supportive careinterventionsareverylimited.Assupportivecareissues areespeciallylargeinpatientswithnon-smallcelllungcancer (NSCLC), lymphoproliferative diseases (LPD), and primary breast cancer (PBC), the occurrence of FN and its impact on health resource utilization and costs were therefore prospectivelyinvestigatedinthisgroupofpatientsinanoninterventionalsetting.
Patients and Methods

Study Design
Thiswasasubgroupanalysisofaprospective,longitudinal,multicentre, observational study [11] with consecutive patient recruiting between January 2005 and December 2006 in 4 Bavarian hospitals in Germany (n = 2 universities; n = 2 standard care). Centres were selected to be experienced in the administration of CTX and represent all levels of current hospital cancer care. Patient follow-up lasted until June 2007. Analysisofresourceconsumptionandcostswasperformedfromthehospital provider's perspective. The study was approved by the hospitals' localethicscommittees,andwritteninformedconsentwasobtainedfrom allpatients.
Patients
Thestudypopulationconsistedofpatientsfulfillingthefollowinginclusion criteria:1stor2ndline(immuno)-CTXforNSCLC,LPD,orPBC.PBC patients had to be undergoing an anthracycline-or taxane-based (neo) adjuvant schedule. To avoid inclusion of patients whose CTX was only initiatedatstudysite,patientshadtobescheduledforatleast2CTXvis-its.PatientsreceivingmyeloablativeCTXwithstemcellsupportwereexcluded,aswerethosewhowereunabletoparticipateinpatientinterviews forlinguisticorcognitivereasons.Recurrentenrolmentwaspossible.
Data Collection
Basic demographics and clinical history at first enrolment as well as anticancer treatment characteristics and toxicity-associated resource usage were collected by pre-planned chart abstraction. Occurrence and severityofCTX-inducedtoxicitywererecordedateachCTXvisitusinga structuredintervieworbytelephoneafterthefinalCTXvisitaccordingto the NCI CTCAE v3.0 and the causality criteria of the World Health OrganisationUppsalaMonitoringCentre(WHO-UMC) [12] .
LaboratorytestsincludingWBCwererecommendedonaweeklybasis. Inthecaseoffever,outpatientswereadvisedtocontacttheirphysicianfor assessmentofhaematologicalcounts.Ifnadirmonitoringwasprovidedby externalinstitutions,awrittendemandrequestingtodisclosenadirblood countswasissuedviathepatient.FNwasincorporatedintoanalysisasa composedvariable.FNwasdefinedasfever≥38ºCandanabsoluteneu-trophil count (ANC) < 1 × 10 9 /l. If nadir ANC was unavailable, febrile leukopenia(FL)wasassessed(leukocytes<2×10 9 /landfever≥38ºC). Granulocyte colony-stimulating factor (G-CSF) use was considered as prophylaxisifstartedbetween24hand120hafterCTX [13] .
Toevaluatecostsfromthehospitalprovider [15, 17] .Similartoourresults,arecentlypublishedSpanishretrospective study reports FN-related costs depending on tumour type [10] . Costs were highest if NHL was the underlying cancer (€ 4,514). For patients with lung and breast cancer, FN-related costs were considerably cheaper (€ 3,310 and € 3,518; significantlyforlungcancerpatients).
In contrast to the mixed breast cancer population (40% stageIV;39%>60years)investigatedbyMayordomoetal.
[10], we studied a cohort of PBC patients (7% ≥ stage III; 21%>65years).Surprisingly,costsperFNepisodewerereduced by half (€ 1,827) and differed significantly from our LPDcohort(€4,808).Similarcostestimateswerefoundina PCBcohortwith1-3positiveaxillarylymphnodes,including 12 toxicity-associated re-hospitalisations with mean direct costs of € 2,209 [18] . Therefore, besides tumour type, other patient-or treatment-related factors seem to influence FNassociatedcosts. Withapproximately23%ofFNepisodesproducing60%of the total economic burden, cost distribution is asymmetric. Therefore,meanFN-associatedcosts(€3,950)markedlydifferfrommediancosts(€2,355).Typically,meancostsserveas costestimatesinhealtheconomicmodels.Overestimationof actualcost-effectivenesscouldbetheconsequence.Thismay becrucialwhenresultsofhealtheconomicmodelsinfluence reimbursementdecisionsandsupportivecareguidelines.
Sincetoxicitymanagementwascoveredmainlybytheparticipating study centres, downstream resource consumption (e.g.consultationofageneralpractitioner)wasestimatedto be low. A considerable proportion of cancer patients in GermanyreceivesanobligatorysickleavefortheentireCTX periodorisalreadyretired.Earlierdatathereforehadshown asmallnumberofworkdayslostattributabletoCTX-induced toxicity [14] . That is why FN-associated indirect costs were notconsideredinthisstudy. frozenplasma,albumin,andantithrombinIIIwerereported in29%ofepisodes.Themostrelevantdiagnosticprocedure wasmicrobiologytesting(79%).
Costs
CostsassociatedwiththemanagementofanFN/FLepisode are presented in table 3, stratified according to cancer type. Mean (median) cost per episode totalled € 3,950 (€ 2,355); 95%CI:€2,568-5,332.Costdriversarebasicperformanceof thedepartment(hospitalization)anddrugs.Theyaccountfor 60and19%,respectivelyofthetotalmeancost.Forpatients with LPD, total mean costs are significantly higher than for PCB patients (€ 4,808 vs. € 1,827). This is mainly due to significantlyhighercostsfordrugs,bloodproducts,andmicrobiologytesting.Meantotalcostsof€3,627perFN/FLepisode occurredforNSCLCpatients.FrequencydistributionofFN/ FL-associatedmanagementcostsis asymmetric;23% of episodes(n=9LPD;n=3NSCLC)generated60%ofthetotal economicburdenintheobservedcohort( fig.3) .Therewere noPCBpatientsinthishigh-costsubgroup.
Discussion
ThisstudyconfirmsthatFN/FLisanexpensivecomplication ofmyelosuppressiveCTX,alsoinGermany.Comparedtothe management of CTX-induced nausea and vomiting, mean costspercycleorepisodewithtoxicityareconsiderablyhigher (€61vs.€3,950)fromahospitalperspective [14] .
Cost of FN Management
FullpublisheddataontheburdenofdiseaseinGermanyafter the introduction of German Diagnosis-Related Groups (GDRGs)in2004arenotavailable.Froma1998Germanhealth insurance perspective, € 2,396 mean FL-associated costs occurredin13smallcelllungcancerpatients(SCLC),aswere € 3,192 in 26 non-Hodgkin's lymphoma (NHL) patients per episodewithneutropenia,fever,and/orinfections [15, 16] . CostAnalysisofFebrileNeutropenia 245 studyconfirmsthatFN/FLhasconsiderableeconomicconsequences for German hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients.Maincostdriversarehospitalizationanddrugs.To improve cost-effectiveness of current supportive care strategies, the impact of clinical characteristics on asymmetrically distributedFNmanagementcostsneedsfurtherevaluation.
Referringtosensitivityanalysesperformedfortheunderlying study [19] , cost results were most sensitive regarding costsofhospitalbasicservices(maximumvariation:±14%).
Clinical Implications and Further Research
Although studies from the United States consistently report higher FN management costs, frequency distribution of FNassociatedlengthofstay-whichdirectlycorrespondstoFNassociated hospitalization costs -was shown to be similarly asymmetric [8] . As a result, predictors for high FN managementcostsshouldcontributetoimprovecost-effectivenessof currentsupportivecarestrategies,irrespectiveofdifferences in health care systems. Patient and treatment characteristics suchasage,leukaemia,hypovolaemia,co-morbidities,andinfectious complications are associated with increased mortality,lengthofstay,andcostduetoFN [8, 20, 21] .Inanadditionalgeneralizedlinearregressionmodelofthisdata,grade ofneutropenia/leukopeniaandCTXlinewereassociatedwith higherFNmanagementcosts.Furtherconfirmatoryresearch with higher sample sizes is warranted. In conclusion, this 
